Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24+CD38hi B Cells
Type I interferon is widely used for antiviral therapy, yet has yielded disappointing results toward chronic HBV infection. Here we identify that PEG-IFNα-2b therapy toward persistent infection in humans is a double-edged sword of both immunostimulation and immunomodulation. Our studies of this rand...
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Frontiers Media S.A.
2020-12-01
|
| Edice: | Frontiers in Immunology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.591269/full |